CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Wang on the Final Results of the ACE-LY-004 Trial in MCL

onclive.com
 2021-09-01

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma. Michael Wang, MD, professor, Department of Lymphoma/Myeloma, founding and current director, Mantle Cell Lymphoma Program of Excellence, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of acalabrutinib (Calquence) in the phase 2 ACE-LY-004 trial (NCT02213926) in mantle cell lymphoma (MCL).

www.onclive.com

Comments / 0

Comments / 0